FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2785442018> ?p ?o ?g. }

• W2785442018 abstract "Biomarkers of Alzheimer's disease (AD) pathology and progression have now been identified across various modalities. The aims of the two studies presented (ANM-MMB and EMIF-AD biomarker discovery) are to discover and replicate previously identified biomarkers of disease pathology and progression, and moreover to determine whether a multimodal biomarker signature may add value in comparison to a biomarker of a single modality. The ANM-MMB cohort is comprised of 718 AD, MCI converters and non-converters, and control subjects selected from the AddNeuroMed, Alzheimer's research trust and Dementia case register cohorts. Cognitive measures, serum and urine metabolomics, structural MRI, genomics, whole blood transcriptomics and plasma proteomics data was available. The EMIF-AD biomarker discovery cohort consists of 1221 AD, MCI and control subjects, selected from the EMIF catalogue. All subjects had existing amyloid measures (CSF Aβ or amyloid-PET), structural MRI and clinical data, and furthermore plasma proteomics (targeted and untargeted), CSF proteomics (targeted), metabolomics, genomics and epigenetics data were generated. For both studies univariate and multivariate statistics were utilised to identify candidate biomarkers of AD pathology (neurodegeneration and/or brain amyloid burden), rates of cognitive decline, and MCI progression to dementia. pQTL-eQTL-mQTL analyses, network/pathway analysis, and multimodal classifiers were employed to detect multimodal signatures. Initial analyses indicate that in the ANM-MMB study a serum and urine derived 15 metabolite classifier predicts MCI progression to AD with 72% accuracy, and the biological significance of the metabolites included in the biomarker panel was identified. Further analyses will examine whether a multimodal classifier is able to predict with even greater accuracy. We will then seek to replicate this in the EMIF-AD biomarker discovery study. Further analyses will also examine single and multimodal biomarker classifiers of other endophenotypes. These two studies could be used to identify novel and replicate previously identified single modality biomarker findings. Furthermore the impact of combining the additional modalities with these findings will be discussed. Computational and technical challenges encountered and the bioinformatics pipeline devised in the multimodal analysis of the ANM-MMB cohort will be used to inform the analysis pipeline of the EMIF-AD biomarker discovery study as a replication." @default.
• W2785442018 created "2018-02-23" @default.
• W2785442018 creator A5002493210 @default.
• W2785442018 creator A5003463212 @default.
• W2785442018 creator A5004136948 @default.
• W2785442018 creator A5004692639 @default.
• W2785442018 creator A5010416832 @default.
• W2785442018 creator A5010752616 @default.
• W2785442018 creator A5010973805 @default.
• W2785442018 creator A5012378779 @default.
• W2785442018 creator A5012553649 @default.
• W2785442018 creator A5014776385 @default.
• W2785442018 creator A5016402702 @default.
• W2785442018 creator A5018434240 @default.
• W2785442018 creator A5019120747 @default.
• W2785442018 creator A5020936422 @default.
• W2785442018 creator A5022295403 @default.
• W2785442018 creator A5023064593 @default.
• W2785442018 creator A5028610237 @default.
• W2785442018 creator A5029875703 @default.
• W2785442018 creator A5034432225 @default.
• W2785442018 creator A5034604069 @default.
• W2785442018 creator A5035920463 @default.
• W2785442018 creator A5036068671 @default.
• W2785442018 creator A5038737675 @default.
• W2785442018 creator A5039782136 @default.
• W2785442018 creator A5041038663 @default.
• W2785442018 creator A5041480057 @default.
• W2785442018 creator A5045725813 @default.
• W2785442018 creator A5045907715 @default.
• W2785442018 creator A5046609202 @default.
• W2785442018 creator A5047831421 @default.
• W2785442018 creator A5049856839 @default.
• W2785442018 creator A5050002274 @default.
• W2785442018 creator A5050015669 @default.
• W2785442018 creator A5050797761 @default.
• W2785442018 creator A5051868596 @default.
• W2785442018 creator A5055048610 @default.
• W2785442018 creator A5055653364 @default.
• W2785442018 creator A5060912586 @default.
• W2785442018 creator A5063533592 @default.
• W2785442018 creator A5066918469 @default.
• W2785442018 creator A5068903009 @default.
• W2785442018 creator A5069668842 @default.
• W2785442018 creator A5071209315 @default.
• W2785442018 creator A5071341444 @default.
• W2785442018 creator A5076585111 @default.
• W2785442018 creator A5079766290 @default.
• W2785442018 creator A5084143852 @default.
• W2785442018 date "2017-07-01" @default.
• W2785442018 modified "2023-10-18" @default.
• W2785442018 title "DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION" @default.
• W2785442018 doi "https://doi.org/10.1016/j.jalz.2017.07.016" @default.
• W2785442018 hasPublicationYear "2017" @default.
• W2785442018 type Work @default.
• W2785442018 sameAs 2785442018 @default.
• W2785442018 citedByCount "0" @default.
• W2785442018 crossrefType "journal-article" @default.
• W2785442018 hasAuthorship W2785442018A5002493210 @default.
• W2785442018 hasAuthorship W2785442018A5003463212 @default.
• W2785442018 hasAuthorship W2785442018A5004136948 @default.
• W2785442018 hasAuthorship W2785442018A5004692639 @default.
• W2785442018 hasAuthorship W2785442018A5010416832 @default.
• W2785442018 hasAuthorship W2785442018A5010752616 @default.
• W2785442018 hasAuthorship W2785442018A5010973805 @default.
• W2785442018 hasAuthorship W2785442018A5012378779 @default.
• W2785442018 hasAuthorship W2785442018A5012553649 @default.
• W2785442018 hasAuthorship W2785442018A5014776385 @default.
• W2785442018 hasAuthorship W2785442018A5016402702 @default.
• W2785442018 hasAuthorship W2785442018A5018434240 @default.
• W2785442018 hasAuthorship W2785442018A5019120747 @default.
• W2785442018 hasAuthorship W2785442018A5020936422 @default.
• W2785442018 hasAuthorship W2785442018A5022295403 @default.
• W2785442018 hasAuthorship W2785442018A5023064593 @default.
• W2785442018 hasAuthorship W2785442018A5028610237 @default.
• W2785442018 hasAuthorship W2785442018A5029875703 @default.
• W2785442018 hasAuthorship W2785442018A5034432225 @default.
• W2785442018 hasAuthorship W2785442018A5034604069 @default.
• W2785442018 hasAuthorship W2785442018A5035920463 @default.
• W2785442018 hasAuthorship W2785442018A5036068671 @default.
• W2785442018 hasAuthorship W2785442018A5038737675 @default.
• W2785442018 hasAuthorship W2785442018A5039782136 @default.
• W2785442018 hasAuthorship W2785442018A5041038663 @default.
• W2785442018 hasAuthorship W2785442018A5041480057 @default.
• W2785442018 hasAuthorship W2785442018A5045725813 @default.
• W2785442018 hasAuthorship W2785442018A5045907715 @default.
• W2785442018 hasAuthorship W2785442018A5046609202 @default.
• W2785442018 hasAuthorship W2785442018A5047831421 @default.
• W2785442018 hasAuthorship W2785442018A5049856839 @default.
• W2785442018 hasAuthorship W2785442018A5050002274 @default.
• W2785442018 hasAuthorship W2785442018A5050015669 @default.
• W2785442018 hasAuthorship W2785442018A5050797761 @default.
• W2785442018 hasAuthorship W2785442018A5051868596 @default.
• W2785442018 hasAuthorship W2785442018A5055048610 @default.
• W2785442018 hasAuthorship W2785442018A5055653364 @default.
• W2785442018 hasAuthorship W2785442018A5060912586 @default.
• W2785442018 hasAuthorship W2785442018A5063533592 @default.
• W2785442018 hasAuthorship W2785442018A5066918469 @default.
• W2785442018 hasAuthorship W2785442018A5068903009 @default.
• W2785442018 hasAuthorship W2785442018A5069668842 @default.

• next